JP2008543853A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543853A5
JP2008543853A5 JP2008517022A JP2008517022A JP2008543853A5 JP 2008543853 A5 JP2008543853 A5 JP 2008543853A5 JP 2008517022 A JP2008517022 A JP 2008517022A JP 2008517022 A JP2008517022 A JP 2008517022A JP 2008543853 A5 JP2008543853 A5 JP 2008543853A5
Authority
JP
Japan
Prior art keywords
compound
formula
administration
daily
corresponds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543853A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/023006 external-priority patent/WO2006138317A2/en
Publication of JP2008543853A publication Critical patent/JP2008543853A/ja
Publication of JP2008543853A5 publication Critical patent/JP2008543853A5/ja
Pending legal-status Critical Current

Links

JP2008517022A 2005-06-17 2006-06-13 プラスグレルのための薬剤投与計画 Pending JP2008543853A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17
PCT/US2006/023006 WO2006138317A2 (en) 2005-06-17 2006-06-13 Dosage regimen for prasugrel

Publications (2)

Publication Number Publication Date
JP2008543853A JP2008543853A (ja) 2008-12-04
JP2008543853A5 true JP2008543853A5 (enExample) 2009-07-30

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517022A Pending JP2008543853A (ja) 2005-06-17 2006-06-13 プラスグレルのための薬剤投与計画

Country Status (18)

Country Link
US (1) US20090156632A1 (enExample)
EP (1) EP1893205A4 (enExample)
JP (1) JP2008543853A (enExample)
KR (1) KR20080016647A (enExample)
CN (1) CN101198329A (enExample)
AU (1) AU2006259538A1 (enExample)
BR (1) BRPI0612624A2 (enExample)
CA (1) CA2612315A1 (enExample)
EA (1) EA200800075A1 (enExample)
EC (1) ECSP078014A (enExample)
GT (1) GT200600263A (enExample)
IL (1) IL187486A0 (enExample)
MA (1) MA29722B1 (enExample)
MX (1) MX2007015430A (enExample)
NO (1) NO20080244L (enExample)
TN (1) TNSN07474A1 (enExample)
WO (1) WO2006138317A2 (enExample)
ZA (1) ZA200710769B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
EP2100610A4 (en) 2006-12-07 2009-12-02 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
ES2769949T3 (es) 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
KR20030014294A (ko) * 2000-07-06 2003-02-15 상꾜 가부시키가이샤 히드로피리딘 유도체 산부가염
PL206138B1 (pl) * 2000-12-25 2010-07-30 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
WO2004098713A2 (en) * 2003-05-05 2004-11-18 Eli Lilly And Company Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)

Similar Documents

Publication Publication Date Title
JP2009533356A5 (enExample)
JP2010518122A5 (enExample)
JP2010270124A5 (enExample)
IL260579A (en) Diagnosis, prevention and treatment of joint diseases
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
WO2007123865A3 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
JP2005520778A5 (enExample)
JP2006501240A5 (enExample)
JP2009525343A5 (enExample)
JP2013542247A5 (enExample)
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
JP2010526837A5 (enExample)
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
EP1077704A1 (en) Combination therapy for treatment of depression
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2010524989A (ja) 関節炎における痛みの治療のためのタペンタドール
JP2013541583A5 (enExample)
JP2012517449A5 (enExample)
JP2008543853A5 (enExample)
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2009507048A5 (enExample)
JP2018039810A5 (enExample)